gefitinib,Osimertinib
astrazeneca
['apple trial', 'detection', 'nsclc', 'sclc', 'gefitinib']
apple trial: in egfrm ansclc , detection of molecular pd (t790m in ctdna ) w/o recist pd during gefitinib is feasible in up to 20% of pts, allowing early switch to osi with 18-mo pfs: 67%. apple is a study. is there a room for sequential ttx? #esmo2022 
Medical Oncologist - Thoracic tumors. Personalized treatment approches @EORTC